Akero Therapeutics reported on their progress in clinical and manufacturing development, highlighting the advancement of AKR-001 and a strong cash position to support its continued development.
Continued clinical and manufacturing progress for Akero.
Rapid progress combined with a strong cash position.
AKR-001 has the potential to become a cornerstone of NASH treatment.
AKR-001 is currently being evaluated in the ongoing Phase 2a BALANCED study.
Akero's forward-looking statements involve risks and uncertainties, and actual results may differ materially from expectations. The company does not undertake any obligation to update these statements.
Analyze how earnings announcements historically affect stock price performance